Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (GB:0HB0)
LSE:0HB0
0HB0 Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.37 - $62.60
Previous CloseN/A
Volume30.00
Average Volume (3M)294.00
Market Cap
$1.86B
Enterprise Value$1.65B
Total Cash (Recent Filing)$76.25M
Total Debt (Recent Filing)$56.99M
Price to Earnings (P/E)3.0
Beta0.53
Next Earnings
May 01, 2025EPS Estimate
-1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.39
Shares Outstanding57,296,165
10 Day Avg. Volume260
30 Day Avg. Volume294
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)50.83
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit51.10
Enterprise Value/Ebitda-3.92
Forecast
1Y Price Target
$56.17Price Target Upside65.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Agios Pharma News
PremiumCompany Announcements
Agios Pharmaceuticals Reports Strong 2024 Financial Results
PremiumCompany Announcements
Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPhase 2 data from the RISE UP study in sickle cell disease have shown highly encouraging results, with superior hemoglobin increase and reduction in vaso-occlusive crises compared to competitors.
Product ExpansionMitapivat, the lead asset of Agios, is expected to have three approved indications by the end of 2026, expanding its potential market significantly.
Bears Say
Safety ConcernsConcerns over hepatocellular injury have negatively impacted AGIO stock, which is down approximately 45% due to these issues observed in thalassemia patients.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.50% Insiders
26.09% Mutual Funds
7.38% Other Institutional Investors
46.88% Public Companies and Individual Investors
0HB0 FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest share price was $27.37 and its highest was $62.60 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $1.86B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is May 01, 2025 which is in 51 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Feb 13, 2025. The company reported -$1.44 earnings per share for the quarter, beating the consensus estimate of -$1.691 by $0.251.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.78.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 57,296,165 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.44 in its last earnings report, beating expectations of -$1.691. Following the earnings report the stock price went down -0.486%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in GB:0HB0
---
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$56.17 (65.74% Upside)
$56.17 (65.74% Upside)
Blogger Sentiment
Bullish
GB:0HB0 Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.21%
12-Months-Change
Fundamentals
Return on Equity
57.29%
Trailing 12-Months
Asset Growth
77.48%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
---
0HB0 Company Deck
---
0HB0 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the development pipeline, with major milestones expected in thalassemia and sickle cell disease. Strong revenue growth from PYRUKYND and a robust financial position are positive indicators. However, higher operating expenses and limited revenue growth for PK deficiency were noted as challenges.Read More>---
0HB0 Stock 12 Month Forecast
Average Price Target
$56.17
▲(65.74% Upside)
Technical Analysis
Best Analysts Covering 0HB0
1 Year
1 Year Success Rate
14/25 ratings generated profit
1 Year Average Return
+16.11%
reiterated a buy rating 12 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 56.00% of your transactions generating a profit, with an average return of +16.11% per trade.
---